Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Li ChenYi-Zhou JiangSong-Yang WuJiong WuGen-Hong DiGuang-Yu LiuJinha YuLei FanJun-Jie LiYi-Feng HouZhen HuCan-Ming ChenXiao-Yan HuangA-Yong CaoXin HuShen ZhaoXiao-Yan MaYing XuXiang-Jie SunWen-Jun ChaiXiaomao GuoXizi ChenYanhui XuXiao-Yu ZhuJian-Jun ZouWen-Tao YangZhong-Hua WangZhi-Ming ShaoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The triplet regimen was efficacious and well tolerated in previously untreated, advanced, immunomodulatory TNBC. The randomized controlled FUTURE-SUPER trial is under way to validate our findings. See related commentary by Salgado and Loi, p. 2728.